Cargando…
The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were ne...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389853/ https://www.ncbi.nlm.nih.gov/pubmed/35982420 http://dx.doi.org/10.1186/s12876-022-02474-9 |
_version_ | 1784770545927061504 |
---|---|
author | Yuichiro, Ohtaki Kan, Uchiyama Hirotaka, Kamiya Eri, Moriizumi Moe, Yamada Yuma, Aoki Toshimune, Watanabe Sachie, Kiryu Sizuka, Suzuki Yoshihiro, Matsumoto Zensho, Ito Toshifumi, Ohkusa Shigeo, Koido Masayuki, Saruta |
author_facet | Yuichiro, Ohtaki Kan, Uchiyama Hirotaka, Kamiya Eri, Moriizumi Moe, Yamada Yuma, Aoki Toshimune, Watanabe Sachie, Kiryu Sizuka, Suzuki Yoshihiro, Matsumoto Zensho, Ito Toshifumi, Ohkusa Shigeo, Koido Masayuki, Saruta |
author_sort | Yuichiro, Ohtaki |
collection | PubMed |
description | BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. RESULTS: The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. CONCLUSIONS: The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX. |
format | Online Article Text |
id | pubmed-9389853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93898532022-08-20 The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis Yuichiro, Ohtaki Kan, Uchiyama Hirotaka, Kamiya Eri, Moriizumi Moe, Yamada Yuma, Aoki Toshimune, Watanabe Sachie, Kiryu Sizuka, Suzuki Yoshihiro, Matsumoto Zensho, Ito Toshifumi, Ohkusa Shigeo, Koido Masayuki, Saruta BMC Gastroenterol Research BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. RESULTS: The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. CONCLUSIONS: The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX. BioMed Central 2022-08-18 /pmc/articles/PMC9389853/ /pubmed/35982420 http://dx.doi.org/10.1186/s12876-022-02474-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yuichiro, Ohtaki Kan, Uchiyama Hirotaka, Kamiya Eri, Moriizumi Moe, Yamada Yuma, Aoki Toshimune, Watanabe Sachie, Kiryu Sizuka, Suzuki Yoshihiro, Matsumoto Zensho, Ito Toshifumi, Ohkusa Shigeo, Koido Masayuki, Saruta The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title_full | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title_fullStr | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title_full_unstemmed | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title_short | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
title_sort | insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389853/ https://www.ncbi.nlm.nih.gov/pubmed/35982420 http://dx.doi.org/10.1186/s12876-022-02474-9 |
work_keys_str_mv | AT yuichiroohtaki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kanuchiyama theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT hirotakakamiya theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT erimoriizumi theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT moeyamada theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yumaaoki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT toshimunewatanabe theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sachiekiryu theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sizukasuzuki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yoshihiromatsumoto theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT zenshoito theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT toshifumiohkusa theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT shigeokoido theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT masayukisaruta theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yuichiroohtaki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kanuchiyama insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT hirotakakamiya insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT erimoriizumi insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT moeyamada insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yumaaoki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT toshimunewatanabe insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sachiekiryu insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sizukasuzuki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yoshihiromatsumoto insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT zenshoito insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT toshifumiohkusa insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT shigeokoido insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT masayukisaruta insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis |